

Orexo

Rodman & Renshaw Conference,
New York
9-11 September, 2009


Orexo – building for profitability

- Two main platforms – Drug Delivery and Discovery
- Strong focus on innovative drug development
- 2 products launched on major markets within the last 12 months - *Abstral*TM (EU) and *Edluar*TM (USA)
- Strong pipeline delivering real value for the long term
- Revenue-generating partnerships with:
 - ProStrakan
 - Kyowa Kirin
 - Meda
 - Boehringer Ingelheim
 - Novartis
- Listed on NASDAQ-OMX Stockholm:
Ticker: ORX; Market capitalization US\$138m⁽¹⁾



Strong position to capture value

orexo



Page 3


* In Partnering discussions

orexo

Abstral™ – showing strong growth in EU

- Sublingual fentanyl tablet for the management of breakthrough cancer pain
- Fast acting and convenient administration
- Partnered in Europe, North America and Japan
- Launched in UK, Germany, France and Sweden – planned launch in Spain in H2 2009
- NDA filed in the US by partner ProStrakan

Breakthrough cancer pain attacks (millions / year⁽¹⁾)






Page 4

1) Source: Datamonitor; Europe includes the five largest markets

orexo

Partnering agreements worldwide

- to capture the full potential of Abstral™



Page 5

orexo

Edluar™ – recently launched in the USA

Product characteristics:

- Short-term treatment of insomnia
- Sublingual tablet, 5 mg and 10 mg zolpidem
- Rapid onset of action

Status:

- Launched in the USA by partner Meda in mid-August
- Priced in line with branded competitors
- Orexo will receive royalty and potentially further sales milestones



MEDA

Page 6

orexo

Sales Joint Venture with ProStrakan

orexo

ProStrakan

Sales company


Focused in Nordic region

50:50 ownership

Revenue Generating



Abstral®
Breakthrough
cancer pain



Rectogesic®
Pain associated
with chronic anal
fissure



Tostrex®
Testosterone gel
for male
hypogonadism



Dridol®
Post-operative
nausea and vomiting

Page 7

orexo

Profitable Orexo Diagnostics subsidiary: **kibion**


- Products for diagnosis of the ulcer-causing bacterium *Helicobacter pylori*
- Sales of USD 3.1 million in H1 2009⁽¹⁾
- Focus on continuing growth and profit



Heliprobe® System

Sales development

USDm⁽¹⁾



Diabact® UBT

Page 8 1) USD translation based on exchange rate of USD/SEK: 7.04 as of August 28, 2009

orexo

Orexo - improved financial result

US\$m ⁽¹⁾ (translation)	H1 2009	H1 2008	FY 2008
Net revenues	20.5	11.4	33.1
Operating Costs	-25.5	-25.0	-49.1
Operating profit	-5.0	-13.6	-16.0
Profit/loss after tax	-4.3	-12.9	-14.6

- Total operating costs in 2009 are expected to be \$43m – \$45m⁽¹⁾
- Following recently-announced efficiency measures and developments in the project portfolio, annual costs are expected to decrease by \$14m in 2010 compared with 2009⁽¹⁾
- \$19.5m in cash reported at end of H1 2009⁽¹⁾

Page 9 1) USD translation based on exchange rate of USD/SEK: 7.04 as of August 28, 2009

orexo

Product portfolio with strong partnerships



ProStrakan
KYOWA KIRIN

Indication: Breakthrough cancer pain
Partners: ProStrakan, Kyowa HAKKO Kirin
Gedeon Richter, Hospira, Novamed, Neopharm



NOVARTIS

Indication: Not disclosed
Stage: Phase II/III



MEDA

Indication: Insomnia
Stage: Launched in the USA
Partners: Meda



**Boehringer
Ingelheim**

Indication: Pain & inflammation
Stage: Preclinical



kibion
(Subsidiary)

Indication: Diagnostic for Helicobacter pylori
Partners: Distribution partners across Europe,
CIS and Middle East



MEDA

Indication: Rhinitis
Stage: Phase III ready

Page 10

orexo

Further partnership opportunities

OX-AAF

Indication: Asthma & COPD
Stage: Preclinical

OX914

Indication: COPD / Asthma
Stage: Phase II

OX-PKX

Stage: Various consumer health
and Rx products
Objective: Big pharma partners

OX219

Indication: Opioid Addiction
Stage: Ready for clinical phase
Objective: Own sales, but license available for Japan

Page 11

orexo

OX17 – innovative new formulation

- Combination of a H2-blocker and a PPI
- Original formulation targeted GERD
- Fast onset and sustained effect
- Global market: USD 28bn⁽¹⁾
- License agreement with Novartis signed in 2009

 **NOVARTIS**



Page 12 ¹⁾ IMS Health

orexo

OX-MPI – NCE against inflammatory pain

- Product description**
- Selective PGE₂ inhibitor
 - Targeting low-side-effect need in inflammatory pain
 - Filling the gap in the market following the COX2 limitations

-
- Market potential**
- Global market: ~USD 10bn⁽¹⁾

-
- Competitive landscape**
- Replacement of NSAIDS/COX2 inhibitors

-
- Competitive advantage**
- Powerful relief from inflammatory pain
 - Good safety profile
 - No CV/GI side effects

-
- Development status**
- Pre-clinical phase
 - Partnered with Boehringer Ingelheim

OX-NLA - Rhinitis



- Product description**
- Liposome formulation - Nasal cetirizine for rhinitis

-
- Market potential**
- Global market USD ~10bn⁽¹⁾

-
- Competitive landscape**
- Direct competitor to Azelastine Nasal Spray (US - MedPointe (also Meda))
 - Azelastine compliance hampered by taste

-
- Competitive advantage**
- Good clinical efficacy
 - Lower sedation than cetirizine tablet

-
- Development status**
- Phase II complete, Phase III ready
 - Worldwide partnership with Meda
 - Double-digit royalty plus potential sales milestones
 - USD 15m milestone when approved by FDA

OX-AAF – Multiple product opportunities

- Product description**
- Selective inhibitors of valid targets in arachidonic acid cascade
 - Targets for asthma, COPD, inflammation
 - Lead program OX-CLI is in pre-clinical stage
-
- Market potential**
- Global market: ~USD 25bn⁽¹⁾
-
- Competitive landscape**
- Singulair, Accolate, Advair , but improved therapeutic action
-
- Competitive advantage**
- Single targets affecting multiple pathways at optimum points
 - Excellent in-vitro efficacy
 - Potential tissue-remodelling prevention
 - Excellent side-effect profiles
-
- Development status**
- Pre-clinical phase
 - Partnering discussions ongoing with Big Pharma partners

OX219 – opportunity for in-house commercialization

- Opioid-addiction therapy drug, containing buprenorphine and naloxone
- Superior to Suboxone™ (Reckitt-Benckiser¹⁾), with significant advantages:
 - Taste
 - Speed of dissolution
 - Easier compliance
 - Lower abuse potential
 - Dosage forms
- Suboxone™ sales are USD ~800m globally
- Currently reformulating product for regulatory route



1) Sold by Schering Plough in EU

Acquisition of PharmaKodex

- Acquisition of PharmaKodex added 4 technologies in line with Orexo's strategy to develop superior, differentiated drugs using effective new and existing drug molecules
- Both Rx and Consumer products under discussion – Rx deal numbers are bigger, but Consumer is lower risk & faster to revenue

Accustar powder sachet



Pandermal applicators



Page 17

orexo

Orexo – covered by 6 equity research houses

Handelsbanken

Erik Hultgård
Accumulate

Nordea

Patrik Ling
Strong Buy

ABG Sundal Collier

Alexander Lindström
Buy

SEB Enskilda

Gustaf Vahlne
Buy

Carnegie

Camilla Oxhamre
Hold


Redeye

Klas Palin
Buy

18

orexo

Share price development since January 2008



1) Index rebased to Orexo's share price as of Jan 1, 2008
Share price development until August 31, 2009

Page 19

orexo

Potential news flow in 2009

- ✓ Filing of Abstral with FDA in USA
- ✓ Definitive license agreement with OX17 Partner
- ✓ Launch of Abstral on additional European markets
- ✓ First formulation partnership with Big Pharma
- ✓ Launch of Edluar in the USA

OX-PKX product license agreement(s)

Partnership deal for OX-AAF program

Next milestone in OX-MPI partnership with BI

Partnership agreement on OX914



Revenue growth expected from Abstral™ and Edluar™

Page 20

orexo

Where is Orexo going?

- Aim is to be a profitable specialty pharma company with reputation for innovation and delivery
- Plan to take 2 products into the clinic each year
- Start selecting products for own account to capture margin
- Find appropriate license partners for other programs
- Looking to expand sales activity with own products
- Find appropriate strategic partners for growth – new products, new acquisitions that cement the strategy



Revenue growth expected from Abstral™ and Edluar™

Page 21

orexo

Thank you

www.orexo.com